Clinical Trial

Adjunctive Fosfomycin for Treatment of Staphylococcus Aureus Bacteraemia

Study acronym: BACSAFO
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 22, 2024 (before its estimated January 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Staphylococcus aureus bacteraemia is a frequent and life-threatening infection, despite current standard antibiotic monotherapy. This study aims to clarify the role of fosfomycin as an adjunctive therapy for improving outcomes in patients with this serious infection. Two clinical trials suggested that adjunctive fosfomycin therapy might offer a clinical benefit in certain cases, but the results are inconclusive. We aim to analyse pooled data from these trials in order to identify subgroups of patients that might benefit most from this therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-18.
Trial Details
NCT Number NCT06695832
Lead Sponsor Hospital Universitari de Bellvitge
Collaborators: Institut d'Investigació Biomèdica de Bellvitge
Conditions Staphylococcus Aureus Bacteremia
Enrollment 369 participants
Start Date 2024-11-01
Primary Completion 2025-01-31 (estimated)
Study Completion 2025-01-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-22